WEZENLA Trademark

Trademark Overview


On Tuesday, March 15, 2022, a trademark application was filed for WEZENLA with the United States Patent and Trademark Office. The USPTO has given the WEZENLA trademark a serial number of 97313068. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Friday, April 12, 2024. This trademark is owned by Amgen Inc.. The WEZENLA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure
wezenla

General Information


Serial Number97313068
Word MarkWEZENLA
Filing DateTuesday, March 15, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateFriday, April 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 4, 2023

Trademark Statements


Goods and Servicespharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 21, 2022
Primary Code005
First Use Anywhere DateThursday, January 1, 1970
First Use In Commerce DateThursday, January 1, 1970

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, US 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, US 913201799

Trademark Events


Event DateEvent Description
Wednesday, December 21, 2022NON-FINAL ACTION E-MAILED
Friday, March 18, 2022NEW APPLICATION ENTERED
Monday, March 21, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, December 14, 2022ASSIGNED TO EXAMINER
Wednesday, December 21, 2022NON-FINAL ACTION WRITTEN
Wednesday, December 21, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 20, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 20, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 21, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 28, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 4, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 30, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, October 2, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 2, 2023SOU EXTENSION 1 FILED
Monday, October 2, 2023SOU EXTENSION 1 GRANTED
Friday, April 12, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 12, 2024SOU EXTENSION 2 FILED
Friday, April 12, 2024SOU EXTENSION 2 GRANTED
Saturday, April 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED